RecruitingNCT02283112

Validation of Drug Assays in Various Biological Matrices

Sponsor

University of Liverpool

Enrollment

100 participants

Start Date

Oct 1, 2014

Study Type

OBSERVATIONAL

Conditions

Infection

Summary

This study aims to ensure that assays that measure drug concentrations are accurate and precise in different matrices when quantified using high performance liquid chromatography -tandem mass spectrometry (HPLC-MS/MS). The study involves collecting samples of various bodily fluids to quantify antimicrobials, antivirals, oral contraceptives and erectile dysfunction agents. Samples will also be obtained from individuals not receiving these medications for quality control purposes.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is working to develop and validate new laboratory methods for measuring drug levels in biological samples such as blood, urine, or saliva. Better drug-level testing helps doctors make sure patients are receiving the right doses of their medications. You may be eligible if... - You are 18 years of age or older - You are able to provide informed consent You may NOT be eligible if... - You are unable to give informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERantivirals, antimicrobials, oral contraceptive, erectile dysfunction agents

Locations(1)

Royal Liverpool University Hospital

Liverpool, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02283112

Related Trials

The Peripheral(-Muscle) Oxygenation and Perfusion Score as a New Non-invasive Tool to Predict Elevations in C-reactive Protein Levels in Neonates

NCT071098561 location

NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD)

NCT051899251 location